TGF-β1 gene transfer to the mouse colon leads to intestinal fibrosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 289, Issue 1 52-1, 2005, Pages

  Vallance, Bruce A ^a   Gunawan, M Imelda ^b   Hewlett, Bryan ^b   Bercik, Premysl ^b   Van Kampen, Corinne ^b   Galeazzi, Francesca ^b,c   Sime, Patricia J ^b   Gauldie, Jack ^b   Collins, Stephen M ^b  

^a BC CHILDREN S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adenovirus; Colitis; Crohn's disease; Epithelial cells; Myofibroblast

Indexed keywords

ADENOVIRUS VECTOR; ALCOHOL; TRANSFORMING GROWTH FACTOR BETA1; BETA GALACTOSIDASE; CENTRAL DEPRESSANT AGENT; ENEMA; LUCIFERASE; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON OBSTRUCTION; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE TRANSFER; HISTOPATHOLOGY; INTESTINAL FIBROSIS; LAMINA PROPRIA; MONONUCLEAR CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENE; ADENOVIRUS; ANIMAL; COLON; CROHN DISEASE; DISEASE MODEL; EPITHELIUM CELL; FIBROBLAST; FIBROSIS; GENETIC TRANSFECTION; GENETICS; GERMFREE ANIMAL; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; LACTOSE OPERON; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COLON; CROHN DISEASE; DISEASE MODELS, ANIMAL; ENEMA; EPITHELIAL CELLS; ETHANOL; FIBROBLASTS; FIBROSIS; HUMANS; INTESTINAL MUCOSA; LAC OPERON; LUCIFERASES; MALE; MICE; PHENOTYPE; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 22844451179     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00051.2005     Document Type: Article

References (68)

1. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, and Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-88, 2002.
2. Assche GV. Can we influence fibrosis in Crohn's disease? Acta Gastroenterol Belg 64: 193-196, 2001.
3. Babyatsky MW, Rossiter G, and Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984, 1996.
4. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 28: 371-390, viii-ix, 1999.
5. Bett AJ, Haddara W, Prevec L, and Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 91: 8802-8806, 1994.
6. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, and Purchio AF. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 264: 13660-13664, 1989.
7. Clouthier DE, Comerford SA, and Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-β1 transgenic mice. J Clin Invest 100: 2697-2713, 1997.
8. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111: 1683-1699, 1996.
9. Dvorak AM, Monahan RA, Osage JE, and Dickersin GR. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 11: 606-619, 1980.
10. Elson CO. The basis of current and future therapy for inflammatory bowel disease. Am J Med 100: 656-662, 1996.
11. Elson CO, Sartor RB, Tennyson GS, and Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344-1367, 1995.
12. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol Gastrointest Liver Physiol 273: G769-G775, 1997.
13. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205, 1998.
14. Fiocchi C. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 108: 523-526, 2001.
15. Foley R, Ellis R, Walker I, Wan Y, Carter R, Boyle M, Braciak T, Addison C, Graham F, and Gauldie J. Intramarrow cytokine gene transfer by adenoviral vectors in dogs. Hum Gene Ther 8: 545-553, 1997.
16. Gauldie J, Sime PJ, Xing Z, Marr B, and Tremblay GM. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol 93: 35-45, 1999.
17. Geboes KP, Cabooter L, and Geboes K. Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastroenterol Belg 63: 371-376, 2000.
18. Graham MF. Pathogenesis of intestinal strictures in Crohn's disease-an update. Inflamm Bowel Dis 1: 220-227, 1995.
19. Gressner AM, Weiskirchen R, Breitkopf K, and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Bioscl 1: 793-807, 2002.
20. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, and Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J Antimicrob Chemother 39: 393-400, 1997.
21. Hamilton T, DeMatteo R, McClane S, Burke C, Rombeau J, and Raper S. Adenoviral-mediated gene transfer to murine small intestine is more efficient in neonates than adults. J Pediatr Surg 32: 373-377, 1997.
22. Hogaboam CM, Chensue SW, Steinhauser ML, Huffnagle GB, Lukacs NW, Strieter RM, and Kunkel SL. Alteration of the cytokine phenotype in an experimental lung granuloma model by inhibiting nitric oxide. J Immunol 159: 5585-5593, 1997.
23. Holtmann MH, Galle PR, and Neurath MF. Immunotherapeutic approaches to inflammatory bowel diseases. Expert Opin Biol Ther 1: 455-466, 2001.
24. Jobin C and Sartor RB. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 6: 206-213, 2000.
25. Karam SM. Lineage commitment and maturation of epithelial cells in the gut. Front Biosci 4: D286-D298, 1999.
26. Kitani A, Fuss IJ, Nakamura K, Schwartz OM, Usui T, and Strober W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta 1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 192: 41-52, 2000.
27. Kolb M, Bonniaud P, Galt T, Sime PJ, Kelly MM, Margetts PJ, and Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol 27: 141-150, 2002.
28. Kolb M, Margetts PJ, Anthony DC, Pitossi F, and Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107: 1529-1536, 2001.
29. Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, Jankovic D, and Sher A. Helicobacter hepaticus triggers colitis in specific-pathogen- free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun 66: 5157-5166, 1998.
30. Lawrance IC, Wu F, Leite AZ, Willis J, West GA, Fiocchi C, and Chakravarti S. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 125: 1750-1761, 2003.
31. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, and Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 12: 2029-2039, 2001.
32. Mastrangeli A, Danel C, Rosenfeld MA, Stratford-Perricaudet L, Perricaudet M, Pavirani A, Lecocq JP, and Crystal RG. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J Clin Invest 91: 225-234, 1993.
33. Macdonald TT. A mouse model of intestinal fibrosis? Gastroenterology 125: 1889-1892, 2003.
34. McKaig BC, Hughes K, Tighe PJ, and Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 282: C172-C182, 2002.
35. Mittal SK, McDermott MR, Johnson DC, Prevec L, and Graham FL. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 28: 67-90, 1993.
36. Miyazono K, Hellman U, Wernstedt C, and Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 263: 6407-6415, 1988.
37. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, and MacDonald TT. Blocking Smad7 restores TGF-beta 1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609, 2001.
38. Ohtani H, Kagaya H, and Nagura H. Immunohistochemical localization of transforming growth factor-beta receptors I and II in inflammatory bowel disease. J Gastroenterol 30, Suppl 8: 76-77, 1995.
39. Otte JM, Rosenberg IM, and Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124: 1866-1878, 2003.
40. Perricaudet M and Stratford-Perricaudet LD. [Adenovirus, a gene therapy vector: application to lung diseases]. Bull Acad Natl Med 179: 463-475; discussion 475-467, 1995.
41. Pickles RJ, Barker PM, Ye H, and Boucher RC. Efficient adenovirus-mediated gene transfer to basal but not columnar cells of cartilaginous airway epithelia. Hum Gene Ther 1: 921-931, 1996.
42. Pizarro TT, Arseneau KO, and Cominelli F. Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am J Physiol Gastrointest Liver Physiol 278: G665-G669, 2000.
43. Podolsky DK. Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterol Belg 60: 163-165, 1997.
44. Present DH. Review article: the efficacy of infliximab in Crohn's disease-healing of fistulae. Aliment Pharmacol Ther 13, Suppl 4: 23-28; discussion 38, 1999.
45. Pucilowska JB, McNaughton KK, Mohapatra NK, Hoyt EC, Zimmermann EM, Sartor RB, and Lund PK. IGF-I and procollagen alpha1(I) are coexpressed in a subset of mesenchymal cells in active Crohn's disease. Am J Physiol Gastrointest Liver Physiol 279: G1307-G1322, 2000.
46. Pucilowska JB, Williams KL, and Lund PK. Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 279: G653-G659, 2000.
47. Raper SE and Wilson JM. Making space for intestinal gene therapy. Gastroenterology 112: 1753-1756, 1997.
48. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, and Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639, 1999.
49. Roberts AB, Flanders KC, Heine UI, Jakowlew S, Kondaiah P, Kim SJ, and Sporn MB. Transforming growth factor-beta: multifunctional regulator of differentiation and development. Philos Trans R Soc Lond B Biol Sci 327: 145-154, 1990.
50. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, and Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117: 761-769, 1999.
51. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, and Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-1338, 2001.
52. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 24: 475-507, 1995.
53. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92: 5S-11S, 1997.
54. Sime PJ, Xing Z, Graham FL, Csaky KG, and Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100: 768-776, 1997.
55. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison CL, Moen RC, Gauldie J, and Graham FL. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther 6: 350-363, 1999.
56. Strober W and Ehrhardt RO. Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell 75: 203-205, 1993.
57. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, and Neurath M. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 18: 61-64, 1997.
58. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N, Gerard C, Grady EF, Bunnett NW, and Collins SM. Neutral endopeptidase (EC 3.42411) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 96: 11653-11658, 1999.
59. Tsang MLS, Weatherbee JA, Dietz M, Kitamura T, and Lucas RC. TGF-beta specifically inhibits the IL-4 dependent proliferation of multifactor dependent murine T-helper and human hematopoietic cell lines. Lymphokine Res 9: 607, 1990.
60. Vallance BA, Radojevic N, Barbara G, Galeazzi F, Graham FL, Gauldie J, and Collins SM. The facilitative role of epithelial barrier disruption in successful gene transfer to the colon (Abstract). Gastroenterology 114: G4517, 1998.
61. Vaquero E, Molero X, Tian X, Salas A, and Malagelada JR. Myofibroblast proliferation, fibrosis, and defective pancreatic repair induced by cyclosporin in rats. Gut 45: 269-277, 1999.
62. Wallace JL and Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol Gastrointest Liver Physiol 258: G527-G534, 1990.
63. Wakefield LM, Smith DM, Flanders KC, and Sporn MB. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem 263: 7646-7654, 1988.
64. Wirtz S, Galle PR, and Neurath MF. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut 44: 800-807, 1999.
65. Wirtz S and Neurath MF. Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther 10: 854-860, 2003.
66. Xing Z, Braciak T, Jordana M, Croitoru K, Graham FL, and Gauldie J. Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of 1L-6 induces lymphocytic hyperplasia in the lung. J Immunol 153: 4059-4069, 1994.
67. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Thorgeirsson SS, and Fukui H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 32: 1248-1254, 2000.
68. Zhao J, Sime PJ, Bringas P Jr, Gauldie J, Warburton D. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol Lung Cell Mol Physiol 277: L412-L422, 1999.